Why Wegovy Has Changed the Landscape of Weight Management

Few medications in recent decades have generated the clinical and public attention that Wegovy has attracted since its approval for weight management. The STEP clinical programme demonstrated results — average weight loss of approximately 15 percent of body weight over 68 weeks — that exceeded what any previously approved pharmacological weight management treatment had achieved. For clinicians treating obesity, this represented a meaningful clinical advance. For patients who had struggled with weight management despite sustained effort, it represented a genuinely new therapeutic possibility. Understanding what Wegovy is, what it does, who it is appropriate for, and what the treatment process actually involves provides the foundation for any informed decision about whether to pursue it.

Wegovy Weight Loss Injection: What It Contains

The Wegovy weight loss injection contains semaglutide at a maintenance dose of 2.4 mg, administered as a weekly subcutaneous injection using a pre-filled auto-injector pen. Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a natural incretin hormone that regulates appetite, gastric emptying, and insulin secretion. The same active ingredient is used in Ozempic at lower doses for type 2 diabetes management, but Wegovy is the formulation approved specifically for chronic weight management in adults with obesity or overweight with comorbidities. The weekly subcutaneous administration through a pre-filled pen makes Wegovy practical for patient self-administration following appropriate training and instruction.

The GLP-1 Mechanism and Why It Works

The GLP-1 receptor agonist mechanism is the pharmacological foundation of Wegovy's efficacy. Natural GLP-1 is produced by L-cells in the small intestine in response to nutrient intake and acts at multiple sites — the hypothalamus, where it reduces appetite and promotes satiety; the stomach, where it slows gastric emptying; and the pancreas, where it stimulates insulin secretion in a glucose-dependent manner. Semaglutide in Wegovy produces sustained activation of these pathways throughout the week between injections — providing continuous appetite suppression that makes caloric restriction substantially more manageable than unmedicated dietary approaches. The result, in combination with dietary modification, is progressive weight loss that continues throughout the treatment period until a steady state is reached.

The STEP Clinical Programme

The STEP trials that established Wegovy's efficacy were conducted across multiple countries with thousands of participants and produced some of the most robust efficacy data in weight management pharmacology. STEP 1 — the pivotal trial — enrolled adults with a BMI of 30 or above, or with a BMI of 27 or above alongside cardiovascular disease risk factors, without type 2 diabetes. Over 68 weeks, participants receiving semaglutide 2.4 mg plus lifestyle intervention achieved average weight loss of approximately 14.9 percent of initial body weight, compared to approximately 2.4 percent with placebo plus lifestyle intervention. Approximately one third of participants achieved 20 percent or more weight loss. These results established Wegovy as the most efficacious approved pharmacological weight management treatment at the time of publication.

Eligibility Assessment for Wegovy

The eligibility criteria for Wegovy in the Netherlands follow the EMA-approved indication — a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition including type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease. The prescribing clinician's assessment goes beyond BMI calculation to include full medical history review, contraindication screening, medication interaction assessment, and evaluation of the patient's understanding of and readiness for the treatment process. Contraindications — particularly personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 — are assessed as part of the standard consultation.

The 16-Week Titration Schedule

The Wegovy dose titration schedule begins at 0.25 mg weekly for 4 weeks and escalates through 0.5 mg, 1.0 mg, and 1.7 mg — each maintained for 4 weeks — before reaching the maintenance dose of 2.4 mg weekly. This 16-week escalation period allows the body to adapt gradually and minimises the intensity of gastrointestinal side effects at each dose level. Patients who experience intolerable side effects at a given dose level can pause escalation at that level for an additional 4 weeks before proceeding. The maintenance dose of 2.4 mg weekly is where the primary therapeutic effect is achieved — the escalation doses are transitional steps, not long-term treatment doses.

Living with Wegovy: The Daily and Weekly Reality

Treatment with Wegovy changes the experience of appetite and hunger in ways that most patients describe as significant. The persistent background hunger that many people with obesity experience — driven in part by metabolic adaptations that increased appetite after any weight loss — is substantially reduced. Portion sizes that feel satisfying are typically smaller than before treatment. Cravings for high-calorie foods may be reduced. For many patients, these effects make the dietary modifications that produce weight loss feel achievable in ways that previous attempts without medication did not. Patients who use these changes to establish healthier dietary patterns during treatment build habits that may contribute to weight maintenance if treatment is eventually discontinued — though the pharmacological benefit of treatment is lost when the medication is stopped.

Injection Technique and Self-Administration

Wegovy injections are given subcutaneously — into the fat layer below the skin — in the abdomen, thigh, or upper arm. The injection site is rotated each week to avoid lipodystrophy at repeated injection sites. The pre-filled pen device delivers the correct dose automatically — the patient positions the pen against the skin, presses the activation button, and holds the pen in place for the required contact time. Healthcare providers provide injection technique guidance as part of the prescribing process, and patients who are uncertain about technique can request demonstration or additional guidance. Pen storage at the appropriate temperature — refrigeration until first use, then room temperature below 30°C for up to 28 days — is also covered in patient guidance.

When Wegovy Stops Working or Is Discontinued

Wegovy produces its therapeutic effect through continuous GLP-1 receptor agonism. When the medication is discontinued, the pharmacological appetite suppression it provides is lost — and weight regain typically follows. The STEP 4 extension trial documented this pattern clearly — participants who switched from semaglutide to placebo after an initial weight loss period regained most of the weight lost within a year. This does not mean Wegovy has failed — it means, like many medications for chronic conditions, it manages a biological condition while it is being taken and the condition returns when treatment stops. Clinicians managing Wegovy treatment discuss this reality with patients as part of the long-term treatment planning process.

The Path to Accessing Wegovy

In the Netherlands, accessing the Wegovy weight loss injection requires a medical consultation, a valid prescription from a registered healthcare provider, and dispensing by a licensed pharmacy. Online medical services that conduct proper clinical assessments provide a legitimate alternative to in-person consultations for patients who prefer this approach. euslimstore.com provides educational information about Wegovy and the medical consultation process for accessing it appropriately.

The Right Choice Starts with the Right Conversation

For anyone considering the Wegovy weight loss injection as a treatment option, the most important first step is a conversation with a qualified healthcare professional who can assess individual eligibility, explain the treatment process, and support the journey with appropriate monitoring and guidance. Visit euslimstore.com to learn more and to find out how to begin the consultation process that is the legitimate starting point for Wegovy treatment.